Intervention Study for Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Following Optimal Debulking Surgery
HEALTHY PARTICIPANTS: No
The purpose of this study is to see how safe and effective four doses of the experimental study drug oregovomab is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.
Who Can Participate
Participants 18 years and older diagnosed with epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin may be eligible for this study.